Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pharmacol Exp Ther ; 328(3): 991-9, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19073910

RESUMO

Overproduction of nitric oxide and activation of soluble guanylate cyclase (sGC) are important in sepsis-induced hypotension and hyporesponsiveness to vasoconstrictors. A time course of the expression and activity of sGC in a sepsis model [cecal ligation and puncture (CLP)] was evaluated in rats. Soluble GC alpha-1 and beta-1 subunit mRNA levels increased in the lungs, but not in the aorta. However, in both tissues, the protein levels increased 24 h after sepsis and remained high for up to 48 h. Sodium nitroprusside-stimulated cGMP accumulation was higher 48 h after CLP in the lung and aorta. NOS-2 protein expression peaked 24 h after CLP, decreasing thereafter. The impact of inhibiting the expression of sGC early (8 h) or late (20 h) on vascular reactivity and the indexes of organ damage and mortality were also studied. Late administration of methylene blue (MB) or ODQ (1H-[1,2,4]-oxadiazole[4,3-a]quinoxalin-1-one) restored the blood pressure and vascular responsiveness to vasoconstrictors to normal levels but was ineffective in early sepsis. Late MB injection reduced the plasma levels of urea, creatinine, and lactate. MB improved the survival if administered late, but it increased the mortality when administrated early after sepsis onset. The increased sGC expression/activity may be relevant for the late hypotension and hyporesponsiveness to vasoconstrictors in sepsis. In accordance, MB increased survival if administered in late sepsis, but not in early sepsis. Therefore, differential responsiveness to sGC during the course of sepsis may determine the success or failure of treatment with sGC inhibitors.


Assuntos
Guanilato Ciclase/antagonistas & inibidores , Sepse/enzimologia , Animais , Aorta Torácica/efeitos dos fármacos , Aorta Torácica/fisiologia , Aorta Torácica/fisiopatologia , Pressão Sanguínea/efeitos dos fármacos , Ceco/patologia , Ceco/cirurgia , GMP Cíclico/metabolismo , Modelos Animais de Doenças , Esquema de Medicação , Inibidores Enzimáticos/uso terapêutico , Feminino , Guanilato Ciclase/genética , Azul de Metileno/uso terapêutico , Mortalidade , Oxidiazóis/uso terapêutico , Quinoxalinas/uso terapêutico , RNA Mensageiro/genética , Ratos , Ratos Wistar , Sepse/mortalidade , Vasoconstrição/efeitos dos fármacos
2.
Micron ; 39(1): 25-31, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-17931871

RESUMO

Toxoplasma gondii is an apicomplexan parasite infecting a broad host range, including humans. The parasite invades host cell by active penetration with the participation of its secretory organelles proteins during this process. Until now, only a limited number of secretory proteins have been discovered, and the effectors molecules involved in parasite invasion and survival are not well understood. Osteopontin (OPN) is a multifunctional glycophosphoprotein, secreted by different cell types, which is involved in various physiological and pathological events including cell signaling and survival. For the first time we demonstrated in this work by immunofluorescence and immunoelectron microscopy approaches the localization of an OPN-like protein in dense granules of extracellular T. gondii tachyzoites. Western blotting and RT-PCR confirmed this protein expression by the parasites. Our results also showed, after macrophage invasion, an intense positive labeling for OPN-like protein at the sub-apical portion of tachyzoites, the site of dense granules secretion, and the localization of this protein at the parasitophorous vacuole membrane. These data suggest that dense granules secrete an OPN-like protein, and we speculate that this protein participates during the parasite interaction process with host cells and parasitophorous vacuole formation.


Assuntos
Grânulos Citoplasmáticos/química , Osteopontina/análise , Proteínas de Protozoários/análise , Toxoplasma/química , Vacúolos/química , Vacúolos/parasitologia , Animais , Western Blotting , Expressão Gênica , Membranas Intracelulares/química , Macrófagos Peritoneais/parasitologia , Camundongos , Microscopia de Fluorescência , Microscopia Imunoeletrônica , RNA Mensageiro/análise , Reação em Cadeia da Polimerase Via Transcriptase Reversa
3.
Int Immunopharmacol ; 6(3): 465-72, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16428082

RESUMO

The mechanisms involved in the mitogenic effect of lectins are not fully understood and are thought to involve a cascade of intracellular signals related to T cell receptor activation. This study shows that frutalin, the alpha-D-galactose-binding lectin from Artocarpus incisa seeds, is a potent mitogenic activator of human lymphocytes. This effect is inhibited by D-galactose and PI3K inhibitors, and is accompanied by an increase in IL-2 receptor expression and by a PI3K-dependent IL-2 gene expression and IL-2 protein synthesis. Frutalin also induces Akt-phosphorylation and activates NF-kappaB, inducing its translocation from the cytosol to the nucleus. Both effects are blocked in the presence of D-galactose or by PI3K inhibitors. In summary, frutalin, interacting with alpha-D-galactose, activates signaling pathways related to TCR, and thereby triggers PI3K/Akt and NF-kappaB pathway, which modulates T cell proliferation, IL-2 synthesis and IL-2R expression. Frutalin might be a useful tool to study intracellular mechanisms following T cell activation that link upstream signaling pathways to downstream events.


Assuntos
Linfócitos/efeitos dos fármacos , NF-kappa B/fisiologia , Fosfatidilinositol 3-Quinases/fisiologia , Lectinas de Plantas/farmacologia , Proteínas Proto-Oncogênicas c-akt/fisiologia , Transdução de Sinais/imunologia , Transporte Ativo do Núcleo Celular/efeitos dos fármacos , Artocarpus , Humanos , Interleucina-2/biossíntese , Interleucina-2/genética , Linfócitos/enzimologia , Mitógenos/farmacologia , Receptores de Interleucina-2/biossíntese , Receptores de Interleucina-2/genética , Sementes , Transdução de Sinais/efeitos dos fármacos
4.
Mol Pharmacol ; 69(3): 983-90, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16326931

RESUMO

We investigated the role of soluble guanylate cyclase in lipopolysaccharide-induced hyporesponsiveness to phenylephrine. The effects of phenylephrine on the blood pressure of female Wistar rats were evaluated at 2, 8, and 24 h after lipopolysaccharide injection (12.5 mg/kg i.p.). Vasoconstrictive responses to phenylephrine were reduced 40 to 50% in all time periods. Methylene blue, a soluble guanylate cyclase inhibitor (15 micromol/kg i.v.) restored the reactivity to phenylephrine in animals injected with lipopolysaccharide 2 and 24 h earlier. However, it failed to do so in animals injected with lipopolysaccharide 8 h earlier. Incubation with sodium nitroprusside (SNP) increased lung and aorta cGMP levels in control animals and in tissues of rats treated with lipopolysaccharide 24 h earlier. However, SNP failed to increase tissue cGMP in rats injected 8 h earlier. Lipopolysaccharide reduced the vasodilatory response to NO donors 8 h after injection. This effect and the decreased lung cGMP accumulation in response to SNP were reversed by an NO synthase blocker. Guanylate cyclase protein levels were lower than controls in lungs harvested from rats injected 8 h earlier and were back to normal values in lungs of rats injected 24 h earlier with lipopolysaccharide. Thus, data indicate that there is a temporal window of 8 h after lipopolysaccharide injection in which soluble guanylate cyclase is not functional and that this loss of function is NO-dependent. Thus, the putative use of soluble guanylate cyclase inhibitors in the treatment of endotoxemia may be beneficial mainly at early stages of this condition.


Assuntos
Endotoxemia/enzimologia , Inibidores Enzimáticos/farmacologia , Guanilato Ciclase/antagonistas & inibidores , Óxido Nítrico/metabolismo , Vasoconstritores/farmacologia , Animais , Aorta/efeitos dos fármacos , Aorta/enzimologia , Pressão Sanguínea/efeitos dos fármacos , GMP Cíclico/metabolismo , Endotoxemia/tratamento farmacológico , Inibidores Enzimáticos/uso terapêutico , Feminino , Lipopolissacarídeos/farmacologia , Pulmão/efeitos dos fármacos , Pulmão/enzimologia , Azul de Metileno/farmacologia , NG-Nitroarginina Metil Éster/farmacologia , Doadores de Óxido Nítrico/farmacologia , Óxido Nítrico Sintase/antagonistas & inibidores , Óxido Nítrico Sintase/metabolismo , Nitroprussiato/farmacologia , Fenilefrina/farmacologia , Ratos , Ratos Wistar , Vasoconstrição/efeitos dos fármacos , Vasoconstritores/uso terapêutico , Vasodilatação/efeitos dos fármacos , Vasodilatadores/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...